ClinicalTrials.gg
CompletedNCT00589979Updated Oct 5, 2017Results posted

Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee

A Phase 2 interventional study of Lidoderm (Lidocaine 5% Patch) and Placebo Patch in Osteoarthritis of the Knee, sponsored by Endo Pharmaceuticals. Completed at 20 sites in United States. Open to participants aged 37 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
37 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
186th of 691
169 · median 72
Started
2007
with 18 others
Phase 2
111 of 796
13 open now
Registered
58th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 186th largest by enrollment of the 691 interventional ones that give a count, is one of 19 that started in 2007, is one of 111 in phase 2, and was the 58th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 37 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

Patients with knee pain due to Osteoarthritis (OA) experiencing sub-optimal pain relief from their current analgesic regimen will participate in a pilot clinical trial to evaluate the effectiveness and tolerability of the Lidoderm Patch compared with placebo in treating knee pain from OA.

03

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • Osteoarthritis
  • Knee
  • Lidoderm
  • Lidocaine
  • Topical patch
  • Adjunct therapy
04

Who can participate

Ages eligible
37 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Male or female patients ≥37 years with moderate-to-severe OA related pain in one knee
  • (BMI) ≤40 kg/m2
  • Symptomatic OA of the index knee diagnosed with a functional capacity of II or III according to ACR criteria classification Note: Patients with symptomatic contralateral knee OA with persistent pain ≤2 cm on a 0-10 cm PI-NRS for ≥2 months will be allowed to participate.
  • Unchanged dose of analgesic medication for OA for at least 4 weeks prior to screening and for the duration of the study
  • Able and willing to complete all paper and e-diary assessments required by protocol

Key Exclusion criteria:

  • Pain in any joint other than the index joint that could interfere with the patient's assessment of pain in the index joint
  • Compromised integrity of the intact, superficial skin layer
  • A grade 1 or 4 Kellgren and Lawrence score on radiographic examination
  • Recent injury to either knee causing pain and interference with daily activities (eg. walking)
  • Recent surgery/procedure to either knee causing pain that could interfere with study assessments of pain, function, and QoL
  • Known or allergy to lidocaine, local anesthetics of the amide type, or any component of the product
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    Lidoderm (Lidocaine 5% Patch)

    Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)

    Drug: Lidoderm (Lidocaine 5% Patch)

  • Placebo comparator
    Placebo Patch

    Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)

    Drug: Placebo Patch

Interventions

06

What researchers measure

Primary outcomes

  1. Time-to-Exit From Current Study Treatment

    Time-to-exit was defined as the number of days at which a patient either met the switching criterion \[a 2-category change in the Pain Relief Scale (PRS) score in the worsening direction (increasing pain or decreasing pain relief) for 2 consecutive days\] or discontinued from the study. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. Traditional survival models that consider event times (e.g. median survival time) as independent and homogeneous across patients were not suitable for this study.

    Time frame: Baseline, Period 1 (up to 4 weeks ±2 days), Period 2 (up to 4 weeks ±2 days), Period 3 (up to 4 weeks ±2 days), or Premature Discontinuation

Secondary outcomes

  1. Time-to-Exit Due to Lack of Efficacy

    Time-to-exit due to lack of efficacy was defined as a patient that met the switching criterion (a 2-category change in Pain Relief Scale (PRS) in the worsening direction \[increasing pain or decreasing pain relief\] for 2 consecutive days) or was discontinued from the current period or study due to lack of efficacy. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. No patients discontinued from the study due to lack of efficacy.

    Time frame: Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation

  2. Exit Status From Current Study Treatment - Yes

    Exit status from a current study treatment was categorized as yes or no for patients who exited prior to the 4-week planned duration. This analysis supports the results of the primary analysis. The number of patients exiting (yes) is reported.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation

  3. Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS)

    The Numerical Rating Scale (NRS) is an 11-point categorical rating scale to assess pain intensity (PI-NRS); 0= no pain and 10= worst possible pain. The scale is anchored on the left with "No Pain" and on the right with "Worst Possible Pain." Patients were to complete this assessment at approximately the same time each day during the double-blind treatment period in their e-diary. The overall treatment difference for the Lidoderm (lidocaine patch 5%) and placebo patch was compared by combining data for patients receiving the respective treatment regardless of the randomized study sequence.

    Time frame: Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)

  4. Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores

    The Pain Relief Scale (PRS) is a 9-point categorical rating scale to assess pain relief during the 24-hours since the last assessment; 0= completely worse and 8= complete pain relief. Patients completed this assessment each day during the run-in period and each day during the double-blind treatment phase in their e-diary.

    Time frame: Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)

  5. Overall Treatment Difference of the LSMeans of the Pain Quality Assessment Scale (PQAS) Scores

    The PQAS measures individual pain qualities and the impact of treatment on those qualities. Items 1-19 are each rated on an 11-point scale ranging from 0 (lowest score - no pain of that type) to 10 (highest score - the highest level of that type of pain). Average surface pain = average of PQAS items: cold, sensitive, itchy, numb, and tingling. Average deep pain = average of PQAS items: dull, cramping, throbbing, aching, and heavy. Average paroxymal pain = average of PQAS items: sharp, shooting, electric, and radiating.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

  6. Patient Global Impression of Change From Baseline in Osteoarthritis (OA) Pain

    Patients rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale indicating: "very much worse" (0); "much worse" (1); "minimally worse" (2); "no change" (3); "minimally improved" (4); "much improved" (5); and "very much improved" (6).

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

  7. Investigator Global Impression of Change From Baseline in Osteoarthritis (OA) Pain

    Investigators rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale ranging from "very much worse" to "very much improved." A similar questionnaire was completed by the Investigator.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

  8. Patient Global Assessment of Treatment Satisfaction

    At the end of each period, patients rated their overall satisfaction with study treatment using a 5-point categorical scale indicating: 0 - very dissatisfied; 1 - dissatisfied; 2 - no preference; 3 - satisfied; and 4 - very satisfied.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

  9. Investigator Global Assessment of Treatment Satisfaction

    At the end of each period, investigators rated their overall satisfaction with study treatment using a 5-point categorical scale ranging from 0 (very dissatisfied) to 4 (very satisfied).

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

Other outcomes

  1. Overall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score

    The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.

    Time frame: Baseline and end of treatment period (up to 4 weeks)

  2. Quality of Life: Four Category Beck Depression Inventory Second Edition (BDI-II) Composite Score

    The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.

    Time frame: Screening, Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

  3. Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores

    Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline (Day 0) and at each clinic visit (at least every 4 weeks) or at premature discontinuation. Values of the EQ-5D index score range from -1 (worst) to 1 (best).

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation

  4. Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS)

    Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Values of the continuous EQ-5D health state today (VAS) ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation

  5. Quality of Life: Three-Category EuroQol Quality of Life Instrument (EQ-5D) General Health Today Compared to Last 12 Months

    Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Categories included Better, Much the Same, and Worse.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation

  6. Overall Treatment Difference in LSMeans for Verran Snyder-Halpern (VSH) Sleep Scale

    The VSH Sleep Scale is contained in a 15 item self-report instrument that measures the quality of a patient's sleep over the last 24 hours. Each item is scored on a 0-100 visual analog scale. The VSH is categorized into 3 sleep scales: disturbance (which measures delays and interruptions in sleep)\[maximum score = 700\], effectiveness (which measures how well sleep refreshed the individual) \[maximum score = 600\], and supplementation (which measures the need for napping) \[maximum score = 400\]. The higher the score the greater the value of the sleep characteristic for that patient.

    Time frame: Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)

07

Results

Posted Sep 22, 2010
Limitations and caveats
Due to operational issues, the modified intent-to-treat (MITT) population, consisting of all intent-to-treat (ITT) patients randomized on or after January 22, 2008, was added to the analysis plan; all efficacy data are presented for this population.

Participant flow

This exploratory, Phase IIb study was initiated on March 6, 2007 at 21 study centers in the United States and completed on June 24, 2008.

Run-In Period
Participant flow — Run-In Period
MilestoneRun-in Period: LidodermTreatment Sequence: Lidoderm - Placebo - PlaceboTreatment Sequence: Placebo - Lidoderm - Lidoderm
Started16900
Completed9300
Not completed7600
Withdrew: Adverse event500
Withdrew: Protocol violation300
Withdrew: Did not qualify for randomization5400
Withdrew: Withdrawal by subject1000
Withdrew: Informed consent withdrawn400
Double-Blind Treatment Period 1
Participant flow — Double-Blind Treatment Period 1
MilestoneRun-in Period: LidodermTreatment Sequence: Lidoderm - Placebo - PlaceboTreatment Sequence: Placebo - Lidoderm - Lidoderm
Started05043
Completed04841
Not completed022
Withdrew: Adverse event010
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject001
Double-Blind Treatment Period 2
Participant flow — Double-Blind Treatment Period 2
MilestoneRun-in Period: LidodermTreatment Sequence: Lidoderm - Placebo - PlaceboTreatment Sequence: Placebo - Lidoderm - Lidoderm
Started04841
Completed04739
Not completed012
Withdrew: Adverse event010
Withdrew: Withdrawal by subject001
Withdrew: Other001
Double-Blind Treatment Period 3
Participant flow — Double-Blind Treatment Period 3
MilestoneRun-in Period: LidodermTreatment Sequence: Lidoderm - Placebo - PlaceboTreatment Sequence: Placebo - Lidoderm - Lidoderm
Started04739
Completed04638
Not completed011
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryTime-to-Exit From Current Study Treatment

Time-to-exit was defined as the number of days at which a patient either met the switching criterion \[a 2-category change in the Pain Relief Scale (PRS) score in the worsening direction (increasing pain or decreasing pain relief) for 2 consecutive days\] or discontinued from the study. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. Traditional survival models that consider event times (e.g. median survival time) as independent and homogeneous across patients were not suitable for this study.

Time frame:
Baseline, Period 1 (up to 4 weeks ±2 days), Period 2 (up to 4 weeks ±2 days), Period 3 (up to 4 weeks ±2 days), or Premature Discontinuation
Reported as:
Median · Days
Time-to-Exit From Current Study Treatment
DaysSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
Period 1 ( Sequence LPP, N=21; Sequence PLL, N=21)31 (10 to 31)20 (12 to 30)
Period 2 (Sequence LPP, N=19; Sequence PLL, N=20)NA (NA to NA)NA (NA to NA)
Period 3 (Sequence LPP, N=19; Sequence PLL, N=19)NA (19 to NA)NA (NA to NA)
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Cox frailty model · p = 0.1006 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Hazard ratio (hr): 1.78 · 95% CI 0.89 to 3.55The Hazard Ratio (HR) provided is the ratio of Placebo to Lidoderm.
SecondaryTime-to-Exit Due to Lack of Efficacy

Time-to-exit due to lack of efficacy was defined as a patient that met the switching criterion (a 2-category change in Pain Relief Scale (PRS) in the worsening direction \[increasing pain or decreasing pain relief\] for 2 consecutive days) or was discontinued from the current period or study due to lack of efficacy. The PRS is a 9-point categorical rating scale to assess pain relief in the last 24 hours in which 0 = completely worse and 8 = complete pain relief. No patients discontinued from the study due to lack of efficacy.

Time frame:
Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Reported as:
Median · days
Time-to-Exit Due to Lack of Efficacy
daysSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
Period 1 (Sequence LPP, N=21; Sequence PLL, N=21)NA (NA to NA)NA (NA to NA)
Period 2 (Sequence LPP, N=19; Sequence PLL, N=20)NA (NA to NA)NA (NA to NA)
Period 3 (Sequence LPP, N=19; Sequence PLL, N=19)NA (NA to NA)NA (NA to NA)
SecondaryExit Status From Current Study Treatment - Yes

Exit status from a current study treatment was categorized as yes or no for patients who exited prior to the 4-week planned duration. This analysis supports the results of the primary analysis. The number of patients exiting (yes) is reported.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Reported as:
Number · Participants
Exit Status From Current Study Treatment - Yes
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
Period 1 (Sequence LPP, N=21; Sequence PLL, N=21)1012
Period 2 (Sequence LPP, N=19; Sequence PLL, N=20)54
Period 3 (Sequence LPP, N=19; Sequence PLL, N=19)62
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Logistic · p = 0.1272 (The logistic regression model for repeated measures used for this analysis included treatment, sequence, period, and first-order carry-over as fixed effects and repeated measures taken on patients nested within sequence.) · Odds ratio (or): 1.86 · 95% CI 0.86 to 4.02The Odds Ratio (OR) provided is the ratio of Lidoderm to Placebo.
SecondaryOverall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS)

The Numerical Rating Scale (NRS) is an 11-point categorical rating scale to assess pain intensity (PI-NRS); 0= no pain and 10= worst possible pain. The scale is anchored on the left with "No Pain" and on the right with "Worst Possible Pain." Patients were to complete this assessment at approximately the same time each day during the double-blind treatment period in their e-diary. The overall treatment difference for the Lidoderm (lidocaine patch 5%) and placebo patch was compared by combining data for patients receiving the respective treatment regardless of the randomized study sequence.

Time frame:
Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS)
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Intensity Numerical Rating Scale (PI-NRS)3.03 ± 0.353.57 ± 0.35
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects model · p = 0.0224 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.54 · 95% CI -1.01 to -0.08The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
SecondaryOverall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores

The Pain Relief Scale (PRS) is a 9-point categorical rating scale to assess pain relief during the 24-hours since the last assessment; 0= completely worse and 8= complete pain relief. Patients completed this assessment each day during the run-in period and each day during the double-blind treatment phase in their e-diary.

Time frame:
Baseline, End of Period 1 (up to 4 weeks), End of Period 2 (up to 4 weeks) and End of Period 3 (up to 4 weeks)
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Overall Treatment Difference in the LSMeans of the Average of the Last Two Daily Pain Relief Scale (PRS) Scores4.45 ± 0.254.06 ± 0.25
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects regression · p = 0.2747 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.39 · 95% CI -0.31 to 1.09The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
SecondaryOverall Treatment Difference of the LSMeans of the Pain Quality Assessment Scale (PQAS) Scores

The PQAS measures individual pain qualities and the impact of treatment on those qualities. Items 1-19 are each rated on an 11-point scale ranging from 0 (lowest score - no pain of that type) to 10 (highest score - the highest level of that type of pain). Average surface pain = average of PQAS items: cold, sensitive, itchy, numb, and tingling. Average deep pain = average of PQAS items: dull, cramping, throbbing, aching, and heavy. Average paroxymal pain = average of PQAS items: sharp, shooting, electric, and radiating.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference of the LSMeans of the Pain Quality Assessment Scale (PQAS) Scores
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Intense3.31 ± 0.323.53 ± 0.32
Sharp2.50 ± 0.343.00 ± 0.34
Hot1.12 ± 0.261.59 ± 0.27
Dull3.04 ± 0.333.28 ± 0.33
Cold0.62 ± 0.140.50 ± 0.14
Sensitive0.88 ± 0.200.96 ± 0.21
Tender2.08 ± 0.301.89 ± 0.30
Itchy0.90 ± 0.231.00 ± 0.23
Shocking1.95 ± 0.342.36 ± 0.34
Numb1.31 ± 0.281.52 ± 0.28
Electrical1.32 ± 0.291.26 ± 0.30
Tingling1.24 ± 0.261.24 ± 0.26
Cramping1.78 ± 0.332.03 ± 0.33
Radiating2.03 ± 0.352.10 ± 0.35
Throbbing2.24 ± 0.342.06 ± 0.35
Aching2.78 ± 0.363.22 ± 0.37
Heavy2.12 ± 0.342.26 ± 0.34
Overall unpleasantness2.98 ± 0.343.55 ± 0.35
Intense deep pain3.33 ± 0.373.77 ± 0.37
Intense surface pain1.61 ± 0.281.82 ± 0.29
Average surface pain0.99 ± 0.151.05 ± 0.15
Average deep pain2.38 ± 0.292.55 ± 0.29
Average paroxysmal pain1.78 ± 0.252.06 ± 0.25
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects model · p = 0.4498 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.22 · 95% CI -0.80 to 0.36The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effect models · p = 0.1065 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.50 · 95% CI -1.11 to 0.11The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) · Linear mixed effects models · p = 0.0484 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.47 · 95% CI -0.94 to -0.00The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) · Linear mixed effect models · p = 0.4973 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.24 · 95% CI -0.93 to 0.46The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effect models · p = 0.3966 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.12 · 95% CI -0.16 to 0.41The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects model · p = 0.6941 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.09 · 95% CI -0.53 to 0.35The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.5664 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.18 · 95% CI -0.45 to 0.82The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.6871 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.09 · 95% CI -0.55 to 0.37The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.2318 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.41 · 95% CI -1.08 to 0.27The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.3383 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.21 · 95% CI -0.64 to 0.22The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.8740 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.05 · 95% CI -0.63 to 0.73The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.9990 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.00 · 95% CI -0.54 to 0.54The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.4183 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.25 · 95% CI -0.85 to 0.36The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.8227 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.07 · 95% CI -0.71 to 0.57The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.5870 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.18 · 95% CI -0.48 to 0.85The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.2181 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.44 · 95% CI -1.15 to 0.27The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.6276 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.13 · 95% CI -0.68 to 0.42The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.0917 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.57 · 95% CI -1.23 to 0.09The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.2089 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.44 · 95% CI -1.13 to 0.25The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.4188 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.22 · 95% CI -0.75 to 0.31The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.6959 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.05 · 95% CI -0.32 to 0.21The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.4806 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.17 · 95% CI -0.64 to 0.30The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.2291 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): -0.28 · 95% CI -0.74 to 0.18The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
SecondaryPatient Global Impression of Change From Baseline in Osteoarthritis (OA) Pain

Patients rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale indicating: "very much worse" (0); "much worse" (1); "minimally worse" (2); "no change" (3); "minimally improved" (4); "much improved" (5); and "very much improved" (6).

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Number · Participants
Patient Global Impression of Change From Baseline in Osteoarthritis (OA) Pain
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
6-Very Much Impr, Period 1 (LPP, N=21; PLL, N=21)35
6-Very Much Impr., Period 2 (LPP, N=19; PLL, N=20)32
6-Very Much Impr., Period 3 (LPP, N=19; PLL, N=19)44
5-Much Improved, Period 1 (LPP, N=21; PLL, N=21)68
5-Much Improved, Period 2 (LPP, N=19; PLL, N=20)98
5-Much Improved, Period 3 (LPP, N=19; PLL, N=19)810
4-Mini. Improved, Period 1 (LPP, N=21; PLL, N=21)74
4-Mini. Improved, Period 2 (LPP, N=19; PLL, N=20)36
4-Mini. Improved, Period 3 (LPP, N=19; PLL, N=19)33
3-No Change, Period 1 (LPP, N=21; PLL, N=21)51
3-No Change, Period 2 (LPP, N=19; PLL, N=20)12
3-No Change, Period 3 (LPP, N=19; PLL, N=19)42
2-Minimally Worse, Period 1 (LPP, N=21; PLL,N=19)03
2-Minimally Worse, Period 2 (LPP, N=19; PLL, N=20)11
2-Minimally Worse, Period 3 (LPP, N=19; PLL, N=19)00
1-Much Worse, Period 1 (LPP, N=21; PLL, N=21)00
1-Much Worse, Period 2 (LPP, N=19; PLL, N=20)20
1-Much Worse, Period 3 (LPP, N=19; PLL, N=19)00
0-Very Much Worse, Period 1 (LPP,N=21; PLL, N=21)00
0-Very Much Worse, Period 2 (LPP, N=19; PLL, N=20)01
0-Very Much Worse, Period 3 (LPP, N=19; PLL, N=19)00
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Linear · p = 0.3185 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Odds ratio (or): 1.32 · 95% CI 0.77 to 2.27The Odds Ratio (OR) provided is the ratio of Lidoderm to Placebo.
SecondaryInvestigator Global Impression of Change From Baseline in Osteoarthritis (OA) Pain

Investigators rated their overall impression of change from Baseline to the end of each period during the double-blind treatment period, including premature discontinuation. Change was rated using a categorical scale ranging from "very much worse" to "very much improved." A similar questionnaire was completed by the Investigator.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Number · Participants
Investigator Global Impression of Change From Baseline in Osteoarthritis (OA) Pain
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
6-Very Much Impr, Period 1 (LPP, N=21; PLL, N=21)34
6-Very Much Impr, Period 2 (LPP, N=19; PLL, N=20)23
6-Very Much Impr, Period 3 (LPP, N=19; PLL, N=19)54
5-Much Improved, Period 1 (LPP, N=21; PLL, N=21)79
5-Much Improved, Period 2 (LPP, N=19; PLL, N=20)108
5-Much Improved, Period 3 (LPP, N=19; PLL, N=19)78
4-Min. Improved, Period 1 (LPP, N=21; PLL, N=21)42
4-Min. Improved, Period 2 (LPP, N=19; PLL, N=20)37
4-Min. Improved, Period 3 (LPP, N=19; PLL, N=19)44
3-No Change, Period 1 (LPP, N=21; PLL, N=21)32
3-No Change, Period 2 LPP, N=19; PLL, N=20)01
3-No Change, Period 3 (LPP, N=19; PLL, N=19)12
2-Minimally Worse, Period 1 (LPP, N=21; PLL, N=21)33
2-Minimally Worse, Period 2 (LPP, N=19; PLL, N=20)10
2-Minimally Worse, Period 3 (LPP, N=19; PLL, N=19)01
1-Much Worse, Period 1 (LPP, N=21; PLL, N=21)11
1-Much Worse, Period 2 (LPP, N=19; PLL, N=20)30
1-Much Worse, Period 3 (LPP, N=19; PLL, N=19)10
0-Very Much Worse, Period 1 (LPP, N=21; PLL, N=21)00
0-Very Much Worse, Period 2 (LPP, N=19; PLL, N=20)01
0-Very Much Worse, Period 3 (LPP, N=19; PLL, N=19)10
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Linear · p = 0.4748 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Odds ratio (or): 1.22 · 95% CI 0.72 to 2.06The odds ratio (OR) provided is the ratio of Lidoderm to Placebo.
Other pre-specifiedOverall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score

The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.

Time frame:
Baseline and end of treatment period (up to 4 weeks)
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Overall Treatment Difference in LSMeans of Beck Depression Inventory Second Edition (BDI-II) Total Score4.41 ± 0.394.29 ± 0.39
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.7839 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.12 · 95% CI -0.74 to 0.98The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
Other pre-specifiedQuality of Life: Four Category Beck Depression Inventory Second Edition (BDI-II) Composite Score

The BDI-II is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression. Patients were to consider each item as it related to the way they felt for the previous 2 weeks. Each of the 21 items corresponding to a symptom of depression was summed to give a single score for the BDI-II, with a 4-point scale for each item ranging from 0-3. A total score of 0-13 is minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Values were based on measurements taken at Screening, at Baseline (Visit 3), and at the end of each period.

Time frame:
Screening, Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Number · Participants
Quality of Life: Four Category Beck Depression Inventory Second Edition (BDI-II) Composite Score
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
Minimal at Screening (LPP, N=21; PLL, N=21)2120
Minimal at Baseline (LPP, N=21; PLL, N=21)2120
Minimal, end of Period 1 (LPP, N=21; PLL, N=21)2119
Minimal, end of Period 2 (LPP, N=19; PLL, N=20)1920
Minimal, end of Period 3 (LPP, N=19; PLL, N=19)1919
Mild at Screening (LPP, N=21; PLL, N=21)01
Mild at Baseline (LPP, N=21; PLL, N=21)01
Mild, end of Period 1 (LPP, N=21; PLL, N=21)01
Mild, end of Period 2 (LPP, N=19; PLL, N=20)00
Mild, end of Period 3 (LPP, N=19; PLL, N=19)00
Moderate at Screening (LPP, N=21; PLL, N=21)00
Moderate at Baseline (LPP, N=21; PLL, N=21)00
Moderate, end of Period 1 (LPP, N=21; PLL, N=21)01
Moderate, end of Period 2 (LPP, N=19; PLL, N=20)00
Moderate, end of Period 3 (LPP, N=19; PLL, N=19)00
Severe at Screening (LPP, N=21; PLL, N=21)00
Severe at Baseline (LPP, N=21; PLL, N=21)00
Severe, end of Period 1 (LPP, N=21; PLL, N=21)00
Severe, end of Period 2 (LPP, N=19; PLL, N=20)00
Severe, end of Period 3 (LPP, N=19; PLL, N=19)00
Other pre-specifiedOverall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores

Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline (Day 0) and at each clinic visit (at least every 4 weeks) or at premature discontinuation. Values of the EQ-5D index score range from -1 (worst) to 1 (best).

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Index Scores0.82 ± 0.010.81 ± 0.01
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects model · p = 0.3773 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 0.01 · 95% CI -0.02 to 0.04The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
SecondaryPatient Global Assessment of Treatment Satisfaction

At the end of each period, patients rated their overall satisfaction with study treatment using a 5-point categorical scale indicating: 0 - very dissatisfied; 1 - dissatisfied; 2 - no preference; 3 - satisfied; and 4 - very satisfied.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Number · Participants
Patient Global Assessment of Treatment Satisfaction
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
4-Very Satisfied, Period 1 (LPP, N=21; PLL, N=21)129
4-Very Satisfied, Period 2 (LPP, N=19; PLL, N=20)810
4-Very Satisfied, Period 3 (LPP, N=19; PLL, N=20)1212
3-Satisfied, Period 1 (LPP, N=21; PLL, N=21)78
3-Satisfied, Period 2 (LPP, N=19; PLL, N=20)96
3-Satisfied, Period 3 (LPP, N=19; PLL, N=20)56
2-No Preference, Period 1 (LPP, N=21; PLL, N=21)13
2-No Preference, Period 2 (LPP, N=19; PLL, N=20)03
2-No Preference, Period 3 (LPP, N=19; PLL, N=20)11
1-Dissatisfied, Period 1 (LPP, N=21; PLL, N=21)11
1-Dissatisfied, Period 2 (LPP, N=19; PLL, N=20)20
1-Dissatisfied, Period 3 (LPP, N=19; PLL, N=20)00
0-Very Dissatisfied, Per. 1 (LPP, N=21; PLL, N=21)00
0-Very Dissatisfied, Per. 2 (LPP, N=19; PLL, N=20)01
0-Very Dissatisfied, Per. 3 (LPP, N=19; PLL, N=19)10
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Linear · p = 0.2605 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Odds ratio (or): 0.71 · 95% CI 0.38 to 1.30The odds ratio (OR) provided is the ratio of Lidoderm to Placebo.
SecondaryInvestigator Global Assessment of Treatment Satisfaction

At the end of each period, investigators rated their overall satisfaction with study treatment using a 5-point categorical scale ranging from 0 (very dissatisfied) to 4 (very satisfied).

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Number · Participants
Investigator Global Assessment of Treatment Satisfaction
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
4-Very Satisfied, Period 1 (LPP, N=21; PLL,N=21)76
4-Very Satisfied, Period 2 (LPP, N=19; PLL, N=20)58
4-Very Satisfied, Period 3 (LPP, N=19; PLL, N=19)811
3-Satisfied, Period 1 (LPP, N=21; PLL,N=21)89
3-Satisfied, Period 2 (LPP, N=19; PLL, N=20)1110
3-Satisfied, Period 3 (LPP, N=19; PLL, N=19)95
2-No Preference, Period 1 (LPP, N=21; PLL,N=21)11
2-No Preference, Period 2 (LPP, N=19; PLL, N=20)11
2-No Preference, Period 3 (LPP, N=19; PLL, N=19)12
1-Dissatisfied, Period 1 (LPP, N=21; PLL,N=21)45
1-Dissatisfied, Period 2 (LPP, N=19; PLL, N=20)20
1-Dissatisfied, Period 3 (LPP, N=19; PLL, N=19)01
0-Very Dissatisfied, Period 1 (LPP,N=21; PLL,N=21)10
0-Very Dissatisfied, Period 2 (LPP,N=19; PLL,N=20)01
0-Very Dissatisfied, Period 3 (LPP,N=19; PLL,N=19)10
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Linear · p = 0.3193 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Odds ratio (or): 0.76 · 95% CI 0.44 to 1.30The odds ratio (OR) provided is the ratio of Lidoderm to Placebo.
Other pre-specifiedOverall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS)

Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Values of the continuous EQ-5D health state today (VAS) ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS)
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Overall Treatment Difference in LSMeans for Continuous EuroQol Quality of Life Instrument (EQ-5D) Health Status Today Using a Visual Analog Scale (VAS)81.1 ± 1.2579.4 ± 1.26
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects model · p = 0.1378 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 1.74 · 95% CI -0.57 to 4.04The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
Other pre-specifiedQuality of Life: Three-Category EuroQol Quality of Life Instrument (EQ-5D) General Health Today Compared to Last 12 Months

Health status was assessed using the EuroQol Quality of Life Instrument (EQ-5D). Patients completed the EQ-5D assessment at Baseline and at the end of each period or at premature discontinuation. Categories included Better, Much the Same, and Worse.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks), or Premature Discontinuation
Reported as:
Number · Participants
Quality of Life: Three-Category EuroQol Quality of Life Instrument (EQ-5D) General Health Today Compared to Last 12 Months
ParticipantsSequence: Lidoderm - Placebo - Placebo (LPP)Sequence: Placebo - Lidoderm - Lidoderm (PLL)
Better Baseline (LPP, N=21; PLL, N=21)114
Better Period 1 (LPP, N=21; PLL, N=21)75
Better Period 2 (LPP, N=19; PLL, N=20)84
Better Period 3 (LPP, N=19; PLL, N=19)96
Much the Same Baseline (LPP, N=21; PLL, N=21)1017
Much the Same Period 1 (LPP, N=21; PLL, N=21)1415
Much the Same Period 2 (LPP, N=19; PLL, N=20)1016
Much the Same Period 3 (LPP, N=19; PLL, N=19)912
Worse Baseline (LPP, N=21; PLL, N=21)00
Worse Period 1 (LPP, N=21; PLL, N=21)01
Worse Period 2 (LPP, N=19; PLL, N=20)10
Worse Period 3 (LPP, N=19; PLL, N=19)01
Statistical analysis
  • Sequence: Lidoderm - Placebo - Placebo (LPP) vs Sequence: Placebo - Lidoderm - Lidoderm (PLL) · Regression, Logistic · p = 0.6833 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Odds ratio (or): 0.88 · 95% CI 0.47 to 1.65The Odds Ratio (OR) provided is the ratio of Lidoderm to Placebo.
Other pre-specifiedOverall Treatment Difference in LSMeans for Verran Snyder-Halpern (VSH) Sleep Scale

The VSH Sleep Scale is contained in a 15 item self-report instrument that measures the quality of a patient's sleep over the last 24 hours. Each item is scored on a 0-100 visual analog scale. The VSH is categorized into 3 sleep scales: disturbance (which measures delays and interruptions in sleep)\[maximum score = 700\], effectiveness (which measures how well sleep refreshed the individual) \[maximum score = 600\], and supplementation (which measures the need for napping) \[maximum score = 400\]. The higher the score the greater the value of the sleep characteristic for that patient.

Time frame:
Baseline, Period 1 (up to 4 weeks), Period 2 (up to 4 weeks), Period 3 (up to 4 weeks)
Reported as:
Least squares mean · Units on a scale
Overall Treatment Difference in LSMeans for Verran Snyder-Halpern (VSH) Sleep Scale
Units on a scaleLidoderm (Lidocaine 5% Patch)Placebo Patch
Disturbance246 ± 13.7224 ± 13.9
Effectiveness303 ± 9.69302 ± 9.85
Supplementation49.7 ± 7.6241.4 ± 7.76
Statistical analysis
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.1143 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 22.16 · 95% CI -5.48 to 49.8The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.9108 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 1.18 · 95% CI -19.8 to 22.2The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.
  • Lidoderm (Lidocaine 5% Patch) vs Placebo Patch · Linear mixed effects models · p = 0.3769 (All statistical tests were 2-sided with a significance level of alpha=0.05.) · Mean difference (net): 8.31 · 95% CI -10.3 to 27.0The results are reported as least squares means and their differences along with associated P-values, and 95% confidence intervals for each fixed effect in the model.

Adverse events

Collected over All adverse events (AEs) were recorded from the beginning of the active Run-in Period through 30 days post-study completion/early termination; a period lasting up to 20 weeks in total.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In Period With Lidoderm (Lidocaine 5% Patch)—1/169 (0.6%)51/169 (30.2%)
Double-Blind Treatment Period With Lidoderm—1/91 (1.1%)24/91 (26.4%)
Double-Blind Active Treatment Period With Placebo—1/91 (1.1%)23/91 (25.3%)
Most frequent serious events
Most frequent serious events
EventRun-In Period With Lidoderm (Lidocaine 5% Patch)Double-Blind Treatment Period With LidodermDouble-Blind Active Treatment Period With Placebo
PneumoniaInfections and infestations1/1690/911/91
Supraventricular extrasystolesCardiac disorders0/1691/910/91
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1690/911/91
Most frequent other events
Showing 10 of 90
Most frequent other events
EventRun-In Period With Lidoderm (Lidocaine 5% Patch)Double-Blind Treatment Period With LidodermDouble-Blind Active Treatment Period With Placebo
Application site reactionGeneral disorders1/1694/911/91
NasopharyngitisInfections and infestations3/1692/913/91
SinusitisInfections and infestations2/1692/913/91
Application site erythemaGeneral disorders2/1691/912/91
Upper respiratory tract infectionInfections and infestations1/1692/910/91
DiarrhoeaGastrointestinal disorders2/1690/912/91
HeadacheNervous system disorders3/1691/910/91
Application site dermatitisGeneral disorders2/1690/910/91
Oedema peripheralGeneral disorders2/1691/910/91
PainGeneral disorders2/1690/910/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence: Lidoderm - Placebo - PlaceboSequence: Placebo - Lidoderm - LidodermTotal
Mean61.1 ± 10.061.1 ± 10.961.1 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Sequence: Lidoderm - Placebo - PlaceboSequence: Placebo - Lidoderm - LidodermTotal
Female322860
Male181533
Region of Enrollment
Region of Enrollment(participants)Sequence: Lidoderm - Placebo - PlaceboSequence: Placebo - Lidoderm - LidodermTotal
United States504393
08

Study locations

20 sites
  • Arizona Arthritis Research, PLC
    Paradise Valley, Arizona 85253, United States
  • NextCare Institute for Clinical Research
    Phoenix, Arizona 85016, United States
  • HOPE Research Institute, LLC
    Phoenix, Arizona 85050, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • New England Research Associates, LLC
    Trumbull, Connecticut 06611, United States
  • Tampa Bay Medical Research, Inc.
    Clearwater, Florida 33761, United States
  • Delray Research Associates
    Delray Beach, Florida 33484, United States
  • CNS Clinical Trials
    Saint Petersburg, Florida 33702, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • Arthritis & Osteoporosis Center of Maryland
    Frederick, Maryland 21702, United States
  • Midwest Pharmaceutical Research
    Saint Peters, Missouri 63376, United States
  • Arthritis Center of Nebraska
    Lincoln, Nebraska 68516, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • University Hospitals of Case Medical Center - Arthritis Translational Research Program
    Beachwood, Ohio 44122, United States
  • Community Research
    Cincinnati, Ohio 45245, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Radiant Research
    San Antonio, Texas 78217, United States
  • Advanced Pain Management & Rehabilitation, Hilltop Medical
    Virginia Beach, Virginia 23454, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jun 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2007
First posted
Jan 10, 2008
Start
Mar 2007
Primary completionActual
Jun 2008
CompletionActual
Oct 2008
Results first posted
Sep 22, 2010
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00589979
Responsible party
Sponsor
First posted
Jan 10, 2008
Start date
Mar 2007
Primary completion
Jun 2008
Completion
Oct 2008
Results posted
Sep 22, 2010
Last update
Oct 5, 2017

Study contacts

Ernest A. Kopecky, PhD, MBA
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion